alfuzosin has been researched along with Disease Exacerbation in 8 studies
alfuzosin: structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effect of alfuzosin 10 mg once daily administered for 2 years on progression events in men with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH)." | 9.12 | Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. ( Roehrborn, CG, 2006) |
| "As we have previously published 4 articles reporting the treatment of 7,093 clinical benign prostatic hyperplasia (BPH) patients treated with alfuzosin in a 3-month open-labelled study which was subsequently extended to 12, 24, and 36 months, the objective of this article is to provide additional data on dropouts, acute urinary retention (AUR), progression to surgery, and safety under the natural conditions of general practice, paying special attention to the predictive factors." | 9.09 | History of 7,093 patients with lower urinary tract symptoms related to benign prostatic hyperplasia treated with alfuzosin in general practice up to 3 years. ( Comet, D; Grange, JC; Lukacs, B; McCarthy, C, 2000) |
| "To investigate in men with benign prostatic hyperplasia (BPH) treated in the general practitioner setting (1) the magnitude and durability of symptom score improvement with alfuzosin; (2) the effect on patients perceived health-related quality of life (HRQL) and sexuality, (3) adverse outcomes and treatment failure; and (4) progression to acute urinary retention and prostate surgery." | 9.08 | Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results. ( Jardin, A; Leplège, A; Lukacs, B; Thibault, P, 1996) |
| "To assess the 3-year efficacy and safety of the selective alpha(1)-blocker alfuzosin at 10 mg once daily in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in 'real-life practice'." | 7.74 | Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. ( Alcaraz, A; Elhilali, M; Emberton, M; Hartung, R; Harving, N; Matzkin, H; Vallancien, G; van Moorselaar, RJ, 2008) |
| "To evaluate the effect of alfuzosin 10 mg once daily administered for 2 years on progression events in men with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH)." | 5.12 | Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. ( Roehrborn, CG, 2006) |
| "As we have previously published 4 articles reporting the treatment of 7,093 clinical benign prostatic hyperplasia (BPH) patients treated with alfuzosin in a 3-month open-labelled study which was subsequently extended to 12, 24, and 36 months, the objective of this article is to provide additional data on dropouts, acute urinary retention (AUR), progression to surgery, and safety under the natural conditions of general practice, paying special attention to the predictive factors." | 5.09 | History of 7,093 patients with lower urinary tract symptoms related to benign prostatic hyperplasia treated with alfuzosin in general practice up to 3 years. ( Comet, D; Grange, JC; Lukacs, B; McCarthy, C, 2000) |
| "To investigate in men with benign prostatic hyperplasia (BPH) treated in the general practitioner setting (1) the magnitude and durability of symptom score improvement with alfuzosin; (2) the effect on patients perceived health-related quality of life (HRQL) and sexuality, (3) adverse outcomes and treatment failure; and (4) progression to acute urinary retention and prostate surgery." | 5.08 | Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results. ( Jardin, A; Leplège, A; Lukacs, B; Thibault, P, 1996) |
| "To assess the 3-year efficacy and safety of the selective alpha(1)-blocker alfuzosin at 10 mg once daily in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in 'real-life practice'." | 3.74 | Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. ( Alcaraz, A; Elhilali, M; Emberton, M; Hartung, R; Harving, N; Matzkin, H; Vallancien, G; van Moorselaar, RJ, 2008) |
| "The progression of benign prostatic hyperplasia (BPH) can be defined as a deterioration of clinical variables such as lower urinary tract symptoms (LUTS), health-related quality of life and peak flow rate, increased prostate size, or unfavourable outcomes such as acute urinary retention (AUR) and BPH-related surgery." | 2.43 | The natural history of benign prostatic hyperplasia. ( Fitzpatrick, JM, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 7 (87.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wiygul, J | 1 |
| Babayan, RK | 1 |
| Armitage, JN | 1 |
| Emberton, M | 3 |
| Fitzpatrick, JM | 1 |
| Roehrborn, CG | 1 |
| Vallancien, G | 1 |
| Alcaraz, A | 1 |
| Matzkin, H | 1 |
| van Moorselaar, RJ | 1 |
| Hartung, R | 1 |
| Harving, N | 1 |
| Elhilali, M | 1 |
| Lukacs, B | 2 |
| Leplège, A | 1 |
| Thibault, P | 1 |
| Jardin, A | 1 |
| Grange, JC | 1 |
| Comet, D | 1 |
| McCarthy, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Long-Term, Efficacy and Safety of Alfuzosin 10 MG OD on the Risk of Acute Urinary Retention and the Need for Surgery in Patients With BPH. A Two Year, Randomized, Multicenter, Double-Blind, Parallel Group, Placebo-Controlled Study.[NCT00029822] | Phase 3 | 1,522 participants (Actual) | Interventional | 2001-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for alfuzosin and Disease Exacerbation
| Article | Year |
|---|---|
Watchful waiting in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Disease Progression; Humans; Male; Prostate; Prostate-Specific Antigen | 2009 |
The natural history of benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Age Factors; Aged; Aged, 80 and over; Controlled Clinical Trials as To | 2006 |
Definition of at-risk patients: dynamic variables.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Disease Progression; Humans; M | 2006 |
3 trials available for alfuzosin and Disease Exacerbation
| Article | Year |
|---|---|
Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
Topics: Adrenergic alpha-Antagonists; Aged; Disease Progression; Double-Blind Method; Humans; Male; Middle A | 2006 |
Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results.
Topics: Adrenergic alpha-Antagonists; Aged; Disease Progression; Family Practice; Humans; Male; Middle Aged; | 1996 |
History of 7,093 patients with lower urinary tract symptoms related to benign prostatic hyperplasia treated with alfuzosin in general practice up to 3 years.
Topics: Adrenergic alpha-Antagonists; Aged; Cohort Studies; Disease Progression; Family Practice; Follow-Up | 2000 |
2 other studies available for alfuzosin and Disease Exacerbation
| Article | Year |
|---|---|
Dynamic variables: novel and perhaps better predictors of progression in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Disease Progression; Humans; Male; Prostatic Hyperplasia; Quinazolines | 2006 |
Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
Topics: Adrenergic alpha-Antagonists; Aged; Disease Progression; Erectile Dysfunction; Humans; Male; Nocturi | 2008 |